Related Experiment Video
Updated: Feb 1, 2026

Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs
Published on: May 24, 2016
Xanthogranulomatous reaction to trametinib for metastatic malignant melanoma
Michelle S Min1, Jonathan Yao2, Nicole Chee3
1Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Abstract:
Trametinib, a mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor, has demonstrated great promise in treating metastatic melanoma associated with BRAF V600E and V600K mutations; however, it also is highly associated with cutaneous adverse events (AEs). As both BRAF and MEK inhibitors become increasingly used to treat malignant melanoma, it is important to better characterize these AEs so that we can manage them. Herein, we present a case of a 66-year-old man who developed erythematous scaly papules on the face and bilateral upper extremities after beginning therapy with trametinib. The severity of the reaction worsened on trametinib monotherapy compared to combination therapy with a BRAF inhibitor. Biopsy revealed a xanthogranulomatous reaction.
Related Concept Videos
Reaction Mechanisms
For instance, the decomposition of ozone appears to follow a mechanism with two steps:
Determining Order of Reaction
Reaction Yield
Reaction Rate
The mathematical representation of the change in the concentration of reactants and products, over time, is the rate...
Reaction Quotient
Half-life of a Reaction

